Cabazitaxel in relapsed high-risk HOrmone-SEnsitive prostate cancer patients. A multicentric Randomized phase II study. C.HO.SE. Trial

Trial Profile

Cabazitaxel in relapsed high-risk HOrmone-SEnsitive prostate cancer patients. A multicentric Randomized phase II study. C.HO.SE. Trial

Discontinued
Phase of Trial: Phase II

Latest Information Update: 03 Sep 2016

At a glance

  • Drugs Cabazitaxel (Primary) ; Antiandrogens; Prednisone
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Therapeutic Use
  • Acronyms CHOSE
  • Most Recent Events

    • 27 Aug 2016 Status changed from recruiting to discontinued.
    • 17 Sep 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top